NewsBenzingaV2X Raises FY2026 Adj EPS Guidance from $5.90-$6.30 to $6.15-$6.55 vs $5.94 Est; Raises FY2026 Sales Guidance from $4.875B-$5.025B to $4.950B-$5.100B vs $4.976B Est V2X Raises FY2026 Adj EPS Guidance from $5.90-$6.30 to $6.15-$6.55 vs $5.94 Est; Raises FY2026 Sales Guidance from $4.875B-$5.025B to $4.950B-$5.100B vs $4.976B Est Benzinga 2026.11.02 21:09 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients